Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 avr. 2026 08h00 HE | Source: ImPact Biotech

ImPact Biotech Presents Preliminary Data from Phase 1 Study of Padeliporfin VTP in LA-PDAC at SIR 2026 and Provides Strategic Business Update

– Initial data from first cohort in LA-PDAC show 66% (2/3) patients resected following VTP at lowest light dose with a consistent and well-tolerated safety profile – – LA-PDAC program represents large...
13 avr. 2026 07h58 HE | Source: Research and Markets

Margenza (MacroGenics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Margenza Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
13 avr. 2026 07h50 HE | Source: Research and Markets

Macugen (Bausch + Lomb: pegaptanib sodium) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Macugen Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
13 avr. 2026 07h48 HE | Source: Research and Markets

Lyumjev (Eli Lilly and Co) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Lyumjev Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
13 avr. 2026 07h46 HE | Source: Research and Markets

LYFGENIA (Bluebird bio: lovotibeglogene autotemcel) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "LYFGENIA Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
13 avr. 2026 07h45 HE | Source: NervGen Pharma Corp.

NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class...
13 avr. 2026 07h30 HE | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment...
13 avr. 2026 07h30 HE | Source: BullFrog AI Holdings, Inc.

BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners

GAITHERSBURG, Md., April 13, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence and...
13 avr. 2026 07h30 HE | Source: MediWound Ltd.

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive...
13 avr. 2026 07h30 HE | Source: Palvella Therapeutics Inc.

Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors

Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership Author of a visionary 2015 Journal of...

Page précédente

Page suivante